期刊
THERAPEUTIC ADVANCES IN HEMATOLOGY
卷 12, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620720987075
关键词
CD38; daratumumab; monoclonal antibody; multiple myeloma; myeloma; newly diagnosed; relapsed refractory; subcutaneous
类别
Daratumumab is a human immunoglobulin G1 kappa monoclonal antibody that targets CD38 and has been approved for use in both newly diagnosed and relapsed refractory multiple myeloma. The subcutaneous formulation of daratumumab has shorter administration time, lower rates of infusion-related reactions, and smaller infusion volume compared to the intravenous formulation. Despite these differences, the pharmacokinetics, safety profile, and efficacy are comparable between the two formulations.
Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with approved anti-myeloma regimens in both newly diagnosed multiple myeloma and relapsed refractory multiple myeloma. Originally developed for intravenous administration, the subcutaneous formulation of daratumumab (daratumumab and hyaluronidase-fihj) was recently approved by the US Federal Drug Administration and European Commission in 2020. In clinical trials, compared with the intravenous formulation, subcutaneous daratumumab (Dara-SC) has significantly shorter administration time (median first dose 7 h versus 3-5 min, respectively), lower rates of infusion-related reactions (median first dose 50% versus less than 10%, respectively), and lower volume of infusion (median 500-1000 ml versus 15 ml, respectively). Otherwise, the pharmacokinetics, safety profile, and efficacy are comparable. This review summarizes the pivotal trials that led to the approval of Dara-SC, highlights important clinical considerations for the use of Dara-SC, and provides practical guidelines for the administration of Dara-SC in the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据